38,915 Results

Winlevi filed with FDA for acne.- Cassiopea

 Added 10 hours ago

Cassiopea has submitted a New Drug Application (NDA) to the FDA seeking marketing approval for Winlevi (clascoterone cream 1%) for...

EPOCH 2 Phase III study of HTX 011 in pain control published in Hernia journal.- Heron Therapeutics

 Added 10 hours ago

Heron Therapeutics announced that the results from EPOCH 2, a Phase III study of the investigational agent HTX 011 (bupivacaine...

Myovant Sciences completes ptient recruitment for phase III SPIRIT 2 study evaluating relugolix combination therapy in women with endometriosis.

 Added 10 hours ago

Myovant Sciences announced that it has completed patient recruitment for its SPIRIT 2 study, the first of two Phase III...

FDA approves Xenleta to treat community-acquired bacterial pneumonia - Nabriva Therapeutics

 Added 10 hours ago

Nabriva Therapeutics plc announced that the FDA has approved Nabriva’s new drug applications for the oral and intravenous (IV) formulations...

Phase III DAPA-HF trial of Farxiga positive for treatment of heart failure.-AstraZeneca

 Added 10 hours ago

AstraZeneca announced positive results from the landmark Phase III DAPA-HF trial which showed that Farxiga (dapagliflozin) met the primary composite...

Congress and Symposia

Transplantation

Congress and Symposia

Antithrombotic Therapy in Patients With Atrial Fibrillation Treated With Oral Anticoagulation Undergoing Percutaneous Coronary Intervention.

The optimal antithrombotic treatment regimen for patients with atrial fibrillation undergoing percutaneous coronary intervention with stent implantation represents a challenge in clinical practice.

ACC/AHA Versus ESC Guidelines on Dual Antiplatelet Therapy: JACC Guideline Comparison.

Dual antiplatelet therapy (DAPT) is the cornerstone of pharmacological treatment aimed at preventing the atherothrombotic complications in patients with a variety of coronary artery disease (CAD) manifestations.

Incidence and severity of coronary artery disease in patients with atrial fibrillation undergoing first-time coronary angiography.

Background: In standard reference sources, the incidence of coronary artery disease (CAD) in patients with atrial fibrillation (AF) ranged between 24 and 46.5%. Since then, the incidence of cardiovascular risk factors (CRF)...

Discharge antithrombotic strategies among patients with acute coronary syndrome previously on warfarin anticoagulation: physician practice in the CRUSADE registry.

Background: Patients experiencing acute coronary syndromes (ACS) with high-risk features frequently undergo percutaneous coronary intervention (PCI) with stent placement, prompting the requisite administration of aspirin and...

Load more